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Case Presentation

The patient is a 49 year-old female with past medical history of
anxiety and hyperlipidemia who presented to an outside hospital
with complaints of five hours of substernal chest pain followed by
three episodes of syncope witnessed by her son. At presentation
in the emergency department the patient denied any current
chest pain or shortness of breath. She received 325 mg of aspirin
en route to the hospital by EMS. Her vital signs were temperature
100° Fahrenheit, heart rate 60 beats/minute, blood pressure
101/50 mm Hg, respiratory rate 20 breaths/minute, and a pulse
oxygenation of 98% on room air. The patient’s EKG showed ST
elevations in the inferior leads. The patient’s laboratory studies
were: white blood cell (wbc) count 14 B/L, hemoglobin 13.2 g/
dL, platelets 153 B/L, CKMB 32 U/L, troponin 8.27 ug/L, and
CK 24.5 U/L. The patient was started on intravenous heparin
and integrillin drips and transferred to Jefferson for emergent
cardiac catheterization.
The patient had left and right coronary angiography which
showed no evidence of occlusive coronary disease. Left heart
catheterization demonstrated moderate to severe inferoapical
hypokinesis and a mildly depressed left ventricular ejection
fraction (40%). During the procedure, the patient was noted to
have 2:1 AV heart block with intraventricular conduction delay,
and a temporary transvenous pacemaker was placed. The patient
was then transferred to the cardiac care unit.
In the cardiac care unit, the patient reported that she had no
known drug allergies. Her only outpatient medication was a
statin that was started six weeks ago. The patient denied any
past surgical history. The patient consumed alcohol socially,
had a 15 pack year history of smoking, and no history of illicit
drug use. The patient’s father died of a myocardial infarction
at age 62, and the patient’s mother was alive with a history of
diabetes mellitus and arrhthymia. The patient noted that she
had some nasal congestion for two days prior to the chest pain
and syncope. The patient also reported working in her garden
with rose bushes and was certain that she had a neck rash due to
poison oak. Lastly, the patient reported decreased oral intake for
the past two days due to “flu-like” disease.
Overnight, the patient had multiple episodes of bradycardia
that warranted venous pacing on telemetry. Significant
laboratory studies were: wbc 4.3 B/L, AST 539 U/L, ALT 313
U/L, and troponin 14.7 ug/L. The patient underwent successful
implantation of a dual chamber VDD pacemaker. A transthoracic
echocardiogram demonstrated an ejection fraction of 60%, mild
to moderate mitral regurgitation, and an inferior vena cava
normal in size without inspiratory collapse. The patient was
transferred to the telemetry floor service.
On the third hospital day, the patient had no overnight complaints
and wanted to be discharged home. Significant laboratory studies

were a troponin of 16.5 and AST 299 U/L, and ALT 250 U/L.
The patient had a CT of her head which showed no fracture or
bleed. A CT of her chest demonstrated multifocal pneumonia
with bilateral pleural effusions and subcentimeter pulmonary
nodules. The patient was diagnosed with pneumonia and was
started on ceftriaxone, azithromycin and flagyl.
On the fourth hospital day, the patient had an overnight fever
of 100.7° Fahrenheit and an episode of oxygen desaturation to
89% on 2 liters oxygen via nasal cannula. Significant laboratory
studies were: wbc 14.9 B/L, troponin 14.1 ug/L, AST 247 U/L,
and ALT 240 U/L.
On the morning of the fifth hospital day, the patient had a fever
of 100.6° Fahrenheit and an episode of tachycardia with oxygen
desaturation to 75% on 2 liters with an increased respiratory
rate (18 to 28 breaths/minute). An arterial blood gas showed
pH 7.50, pCO2 23, PO2 138, HCO3 18, O2 sat 99%. Significant
laboratory studies were wbc 18.9 B/L, troponin 8.9 ug/L, AST
279 U/L, ALT 288 U/L, lactate 40.8 mmol/L, and BNP 2058.
The patient was treated with nebulizer treatments, intravenous
furosemide, and an anxiolytic. A transthoracic echocardiogram
demonstrated an ejection fraction of 25%, moderate-severe
mitral regurgitation, severely decreased left ventricular systolic
function with segmental wall motion abnormalities, mild
right atrial enlargement, dilated inferior vena cava, and right
ventricular enlargement with decreased function.
Later in the afternoon, the patient had complaints of shortness
of breath and increased anxiety. Vital signs at the time were
heart rate 123 bpm, blood pressure 100/60 mm Hg, respiratory
rate 36 breaths/minute, pulse oxygenation of 90% on 100% nonrebreather mask. An arterial blood gas demonstrated pH 7.49,
pCO2 27, PO2 60, HCO3 20, O2 sat 93%. The patient was once
again treated with nebulizer treatments, intravenous lasix and had
symptomatic relief. Three hours later, the patient had worsening
respiratory distress and was found to have a respiratory rate of
48-60 with a pulse oxygenation of 68% on room air and 88%
on 100% non-rebreather mask. A rapid response was called for
worsening respiratory distress.
The patient was transferred to the cardiac care unit and emergently
intubated. Subsequently, the patient became progressively
hypotensive and a central line was placed, and intravenous
norepinephrine was started. The patient was presumed to have
worsening sepsis secondary to multifocal pneumonia with
cardiomyopathy of sepsis. Antibiotic coverage was broadened to
vancomycin and zosyn. In addition, doxycycline was added to
cover possible ricketsial infections. A complete rheumatologic
and autoimmune work up was sent for laboratory studies.
The following day, the patient had a transesophageal echocardiogram which showed no vegetations. Azithromycin was
added to cover atypical organisms, and the patient was started
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on an acute respiratory distress syndrome ventilator protocol.
Significant laboratory studies were: wbc 23.1B/L with 6% bands,
AST 1209 U/L, ALT 873 U/L, and troponin 6.29 ug/L.

conducted during the surgical procedure. A collection of all lab
results is included in Table 1.

On the seventh day, the patient underwent fiberoptic
bronchoscopy which was grossly normal and bronchoalveolar
lavage of the right upper lobe was sent for cultures. Significant
laboratory studies were: wbc 19.1 U/L, creatinine 1.5 umol/L, AST
2220 U/L, and ALT 1516 U/L. The patient became progressively
more hypotensive, and the norepinephrine drip was titrated.
The patient also had decreasing urine output and worsening
transaminitis was thought to be due to ischemic hepatitis.

Often, myocarditis is an under-diagnosed medical condition. Its
pathophysiology is marked by a triad: cardiac injury by inciting
agent, immunologic response, and inflammation. Generally
speaking 1/3rd of patients recover, 1/3rd experience permanent
cardiac dysfunction, and 1/3 rd deteriorate to either death or
cardiac transplant.

On the eighth day, the patient developed a supraventricular
tachycardia which was treated with adenosine and revealed
an underlying atrial flutter rhythm. The patient was started
on digoxin for rate control. With worsening hypotension
and tachycardia, the patient was started on phenylephrine
with plans to wean down norepinephrine. Due to worsening
clinical status, Xigris therapy was also initiated. A transthoracic
echocardiogram showed an ejection fraction of 10%, moderatesevere mitral regurgitation, severe left ventricular systolic
function (with only the basal-inferolateral segment contracting
– the remainder was hypokinetic/akinetic), right ventricular
enlargement, moderate-severe tricuspid regurgitation. Late in
the evening, the patient’s clinical exam had a significant change
with cool extremities and hypothermia. Laboratory studies were
consistent with a state of disseminated intravascular coagulation
and worsening renal function. A family meeting was called
to discuss the worsening clinical status and overall prognosis.
Cardiology consultation offered right heart catheterization and
the placement of an intraortic balloon pump (IABP). The right
heart catheterization showed HR 130, aortic pressure 91/59, PA
55/39 mean 45, wedge 54, RA 50/49 mean 40, RV 55/39, SVR
750, PVR 1126, CO by Fick 3.20, CI by Fick 1.59. The patient
was diagnosed with cardiogenic shock, and the IABP was set
at 1:1 and a Shiley catheter was placed for urgent continuous
veno-venous hemodialysis. The patient was weaned off of the
phenyephrine and started on dobutamine, dopamine, and
eventually epinephrine.
On the morning of the ninth hospital day, the cardiac care unit,
heart failure, pulmonary, renal, and cardiothoracic surgery
teams discussed the patient’s case. Significant laboratory
studies were: wbc 21 U/L, hemoglobin 7.9 g/dL, platelets 59 B/
L, creatinine 2.5 umol/L, and AST 12217 U/L, and ALT 4060 U/
L. Due to the rapid and progressive decline in cardiac function
due to severe myocarditis, a decision was made to place a
right ventricular assist device (RVAD) and a left ventricular
assist device (LVAD), commonly called a BiVAD. The patient
underwent surgery with the RVAD connecting the right atrium
to the pulmonary arteries and the LVAD connecting the left
ventricle to the aorta. A cardiac myocardial biopsy was also
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Discussion

Myocarditis’ true incidence is most likely under represented. It has
been postulated that up to 8.6% of sudden cardiac deaths may be
attributable to myocarditis.1 Up to 10% to 40% of what was thought
to be idiopathic dilated cardiomyopathy in children may in fact be
occult myocarditis.2 As diagnostic techniques such as immunohistochemistry, electron microscopy, and molecular proteomics
advance inevitably the incidence of myocarditis will rise.
The diagnosis most often implies viral infection. The most
common vectors of disease have thought to be enteroviruses
such as coxsackie or adenovirus. However, any virus can cause
myocarditis: cytomegalovirus, parvovirus, influenza, human
immunodeficiency virus, hepatitis C, and Epstein-Barr virus
have all been implicated. Furthermore, tricyclic antidepressants,
clozapine, the smallpox vaccine, radiation, heat stroke, and
hypothermia can all cause inflammation of cardiac tissue.
Clinically, the onset of symptoms can be insidious or rapid.
Acutely, a viral prodrome often predominates with signs
including fatigue, arthralgias, and fever. After this, cardiac
manifestations may develop. In this particular case our patient
presented with arrhythmia and heart block, which can be seen
as the presenting symptom in 5% of cases.3 Other symptoms
such as chest pain and heart failure are often also present.
Unfortunately, some patients may present with hemodynamic
compromise and a fulminant picture.
Laboratory testing can include elevated ESR, WBC, or troponin.
EKG findings are often non-specific and may range from
subtle abnormalities to ST elevations. One study revealed that
in the setting of an acute myocardial infarction and normal
cardiac catheterization, 38% of patients were thought to have
myocarditis.4 Non-invasive techniques include transthoracic
echocardiography in which regional wall motion abnormalities
are typically more common than cardiac dilation. This is
especially true in the acute to sub-acute period before cardiac
remodeling has occurred. A less common used modality is
indium-111 anti-myosin imaging. This is a nuclear medicine
study in which anti-myosin antibodies are introduced, they
bind to injured myocardium, and the results can then be
quantified. The technique is excellent for detecting damage;
however, distinguishing between a myocardial infarction and
myocarditis may be difficult. In fact, the sensitivity is good at
85% to 100%, but the specificity is only 55%.5 Another option
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Table 1. Laboratory results
Infectious

Cardiovascular

Hepatology

Legionella Ag negative

Cholesterol 190

Hep A IgG/IgM negative

Lyme disease Ab 0.12 (negative)

HDL 33

Hep B IgG/IgM negative

Lyme PCR negative

LDL 120

Hep B core Ab negative

M.Pneumoniae IgM negative

Triglycerides 187

Hep B surface Ab negative

Ehrlichia Ab IgG/IgM negative

Hep C Ab negative

RPR negative

Rheumatology

Hep C PCR negative

HIV negative

RF 21 (wnl)

Alpha-1 antitryp quant 251 (high)

EBV IgM negative

ACE 21 (wnl)

Copper 47.7 (high)

EBV IgG positive

ANA negative

EBV nuclear Ab positive

anti dsDNA 11 (wnl)

Hematology

CMV negative

ASM negative

Serotonin release negative

Herpes negative

C-ANCA negative

PLT factor 4 negative

RSV negative

P-ANCA negative

Iron 52 (wnl)

Varicella IgG Ab reactive

TIBC 252 (low)

VZV IgM 0.16 (negative)

Endocrinology

FeSat 24% (low-normal)

Coxsackie types negative

HgbA1C 5.7%

Ferritin 1085 (high)

Ent-virus PCR negative

TSH 0.65 (wnl)

Influenza A+B negative

Cortisol 94

CMV Ab IgM negative
Toxoplasma negative

is cardiac MRI which uses contrast kinetics to identify areas of
damage and may be able to differentiate myocardial infarction
from myocarditis. Epicardial predominance, a non-contiguous
pattern, and involvement of the lateral wall are more common
in myocarditis according to one study.6
The gold standard in the diagnosis of myocarditis is biopsy. For 20
years, the Dallas criteria have defined a positive biopsy as one that
displays inflammatory cells plus necrosis. A borderline biopsy is
one that has inflammatory cells but no necrosis.7 However, this
system is imperfect. The nature of myocarditis is such that it does
not involve the entire myocardium. As such, even if one takes five
biopsy specimens, the diagnosis will be missed 33% of the time.8
Moreover, the disease often affects the lateral wall which is difficult
to biopsy using current techniques. Detection of myocarditis via
pathology can also be subject to observer differences. Furthermore,
there are risks involved with the procedure such as vascular access
issues, arrhythmias, and perforation.
Prognosis generally depends on the type of myocarditis. For
example, giant cell myocarditis usually progresses quite rapidly,

while other forms progress more subtly. As stated previously,
patients may recover completely, sub-acutely progress to
permanent cardiac dysfunction, or rapidly deteriorate to death
or transplant. Generally, there is a 20% mortality at one year and
50% at four years. Predictors of death or requiring transplantation in the future include the presenting symptom of syncope
or bundle branch block, an ejection fraction of <40%, and
persistence of viral genome in the myocardium.9 Unfortunately,
our patient had two of these three predictors.
Regrettably, the treatment options for myocarditis leave much
to be desired. The first steps are supportive therapies such as
ACE inhibitors, diuretics, and beta blockers when clinically
stable. The National Institutes of Health conducted a trial in
which they randomized standard heart failure therapy versus
steroids + azathioprine versus steroids + cyclosporine for six
months. The results showed no difference in ejection fraction
or mortality after four years.10 There was some improvement
during the acute treatment phase, but this was transient. Final
recommendations included considering steroids in giant cell
myocarditis or in hemodynamic compromise. In another trial,
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interferon was used to treat 22 patients for six months. Virus
was eliminated from myocardium in all 22 patients and 15 of 22
showed improvement in left ventricular systolic function.11 The
results were fairly promising and, consequently, have spurred
an ongoing phase III trial. IVIG has been sought as therapy due
to its effects on auto-antibodies. In 2003, IVIG was compared
to placebo. Systolic function improved from 25% at baseline
to 41% at six months, but there was no statistical difference
in the two arms of the trial.12 Currently, the most recognized
treatments are supportive. Specifically, left ventricular assist
devices have been shown to be beneficial in select patients.
Indications for LVAD include: cardiac index < 2.0L/min/m2,
central venous pressure or left atrial pressure >20, and urine
output <20mL/hour despite maximal pharmacological therapy.13
Furthermore, the disease may be so progressive that both right
and left ventricular assist devices may be needed, such as in this
case presented here. Indications for a BiVAD are renal, hepatic,
and pulmonary dysfunction, seen with our patient.14
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